Structural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate Phases
- 13 March 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 12 (4), 2122-2126
- https://doi.org/10.1021/cg300152p
Abstract
Crystal structures for the commercial monohydrate form and an anhydrate form of dasatinib, an oral anti-cancer agent, are presented along with characterization by Raman spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and thermogravimetric analysis. Solubility measurements conducted in water reveal the anhydrate has dramatically improved solubility compared to the commercial hydrate form. Finally, dasatinib is a rare example of a promiscuous solvate former and the basis for this behavior can now be understood by examining the poor packing efficiency in the unsolvated form.Keywords
This publication has 17 references indexed in Scilit:
- Toward an Understanding of the Factors Influencing Anhydrate-to-Hydrate Transformation Kinetics in Aqueous EnvironmentsCrystal Growth & Design, 2008
- Conformational Polymorphism in Organic CrystalsAccounts of Chemical Research, 2008
- Influence of Solid Phase and Formulation Processing on Stability of Abbott-232 Tablet FormulationsJournal of Pharmaceutical Sciences, 2006
- 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase InhibitorJournal of Medicinal Chemistry, 2006
- Dissecting the Behavior of a Promiscuous Solvate FormerAngewandte Chemie-International Edition, 2006
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Drug polymorphism and dosage form design: a practical perspectiveAdvanced Drug Delivery Reviews, 2004
- Crystalline solidsAdvanced Drug Delivery Reviews, 2001
- Pharmaceutical hydratesThermochimica Acta, 1995